Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promisingtreatments

Statistics in Medicine

Volumn 32, Issue 7, 2013, Pages 1150-1163

  Jaki, T ^a   Magirr, D ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Confidence intervals; Dunnett test; Multi arm, multi stage; Ordinal; Time to event

Indexed keywords

TELMISARTAN;

ANALYTICAL ERROR; ARTICLE; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; COVARIATE; EFFECT SIZE; ENDPOINT; EXPLANATORY VARIABLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; NULL HYPOTHESIS; RESPONSE VARIABLE; SAMPLE SIZE; SIMULATION; STATISTICAL MODEL; STATISTICAL PARAMETERS; STUDY DESIGN;

BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; CONFIDENCE INTERVALS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; ENDPOINT DETERMINATION; HUMANS;

EID: 84874954513     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5669     Document Type: Article

References (30)

1. Barthel FM, Parmar MKB, Royston P. How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design - a reanalysis of 4 trials. Trials 2009; 10:21.
2. Antonijevic Z, Pinhero J, Fardipour P, Lewis RJ. Impact of dose selection strategies used in phase II on the probability of success in phase III. Statistics in Biopharmaceutical Research 2010; 2:469-486.
3. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63:655-660.
4. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18:1833-1848.
5. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 24:3697-3714.
6. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Wiley: Chichester, 1997.
7. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall: Boca Raton, 2000.
8. Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparitive clinical trials. Biometrika 1988; 75:303-310.
9. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22:689-703.
10. Follmann DA, Proschan MA, Geller NL. Monitoring pairwise comparisons in multi-armed clinical trials. Biometrics 1994; 50:325-336.
11. Stallard N, Friede T. A group-sequential design for clinical trials with treatment selection. Statistics in Medicine 2008; 27:6209-6227.
12. Chen, Lan, DeMets Some drop-the-loser designs for monitoring multiple doses. Statistics in Medicine 2010; 29(17):1793-807.
13. Magirr D, Jaki T, Whitehead J. A generalised Dunnett test for multi-arm, multi-stage clinical studies with treatment selection. Biometrika 2012; 99(2):494-501.
14. Graybill FA. Theory and Application of the Linear Model. Duxbury Press: North Sciutate, Massachusetts, 1976.
15. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
16. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
17. Jaki T. MAMS: Designing Multi-arm Multi-stage Studies, 2012. http://CRAN.R-project.org/package=MAMS, R package version 0.2.
18. Dunnett CW. Selection of the best treatment in comparison to a control with an application to a medical trial. In Design of Experiments: Ranking and Selection, Santer TJ, Tamhane AC (eds). Marcel Dekker: New York, 1984; 47-66.
19. Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of the adaptive and of classical group sequential approaches. Biometrics 2001; 57:886-891.
20. Parsons N. asd: simulations for adaptive seamless designs, 2010. http://CRAN.R-project.org/package=asd, R package version 1.0.
21. McCullagh P. Regression models for ordinal data (with discussion). Journal of the Royal Statistical Society, Series B 1980; 42:109-142.
22. Dark R, Bolland K, Whitehead J. Statistical methods for ordered categorical data based on a constrained odds model. Biometrical Journal 2003; 45:453-470.
23. Whitehead J, Jaki T. One- and two-stage design proposals for a phase II trial comparing three active treatments with a control using an ordered categorical endpoint. Statistics in Medicine 2009; 28:828-847.
24. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64:191-199.
25. Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983; 39:227-236.
26. Tsiatis AA. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. Biometrika 1981; 68(1):311-315.
27. Collett D. Modelling Survival Data in Medical Research, (2nd edn). Chapman and Hall/CRC: Boca Raton, 2003.
28. Whitehead J. Predicting the duration of sequential survival studies. Drug Information Journal 2001; 35(4):1387-1400.
29. Stallard N. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Statistics in Medicine 2010; 29(9):959-971.
30. Bauer P, Koenig F, Brannath W, Posch M. Selection and bias - two hostile brothers. Statistics in Medicine 2010; 29:1-13.